Education
About Us
Working with TipRanks
Follow Us
LifeVantage Corp (LFVN)
NASDAQ:LFVN
Top Page
LifeVantage
(NASDAQ:LFVN)
71Outperform
LifeVantage (LFVN) vs. S&P 500 (SPY)
Market Cap
$192.03M
Dividend Yield1.15%
Average Volume (3M)174.18K
Price to Earnings (P/E)27.1
Beta (1Y)-0.20
Revenue Growth0.57%
EPS Growth155.00%
CountryUS
Employees222
SectorConsumer Defensive
Sector Strength86
IndustryPackaged Foods
Share Statistics
EPS (TTM)0.56
Shares Outstanding12,551,281
10 Day Avg. Volume174,444
30 Day Avg. Volume174,175
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)N/A
Price to Sales (P/S)0.91
Price to Cash Flow (P/CF)5.30
P/FCF Ratio5.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$30.00Price Target Upside117.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
LifeVantage Business Overview & Revenue Model
Company DescriptionLifeVantage Corporation (LFVN) is a science-based network marketing company that focuses on nutrigenomics and biohacking products. The company develops dietary supplements and skincare products designed to improve health and wellness by addressing oxidative stress and other physiological processes. LifeVantage's flagship product, Protandim, is a patented dietary supplement aimed at activating the body's pathways to enhance its natural defenses against cellular stress.
How the Company Makes MoneyLifeVantage primarily generates revenue through direct sales and a network marketing model. The company sells its products via independent distributors who earn commissions based on their sales and the sales of their recruited team members. This multi-level marketing structure incentivizes distributors to expand their networks, driving product sales and revenue growth. Key revenue streams include sales of its flagship products like Protandim and its skincare line, as well as subscription-based offerings that provide recurring revenue. LifeVantage's earnings are also influenced by its strategic partnerships and global market expansion efforts.
LifeVantage Financial Statement Overview
Summary
LifeVantage demonstrates strong cash flow management and a solid balance sheet with prudent leverage. While there is efficient cost management and good asset utilization, the company needs to address inconsistent revenue growth and modest profit margins.Income Statement
The TTM gross profit margin is strong at 79.78%, indicating efficient cost management. However, the net profit margin stands at a modest 3.46%, suggesting room for improvement in controlling other expenses. Revenue growth has been inconsistent, with a slight decline recently. EBIT and EBITDA margins are moderate, reflecting average operational efficiency.68
Positive
Balance Sheet
The company maintains a healthy equity ratio of 43.61%, indicating good financial stability and asset management. The debt-to-equity ratio is 0.43, demonstrating conservative leverage. Return on equity is modest at 24.56%, suggesting a decent return on shareholders’ investments.75
Positive
Cash Flow
The operating cash flow to net income ratio is robust at 1.95, showing strong cash generation relative to net income. Free cash flow growth is positive, and the free cash flow to net income ratio of 1.75 suggests healthy cash flow management supporting business operations.80
Positive
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 212.15M | 200.16M | 213.40M | 206.36M | 220.18M | 232.91M | Gross Profit |
| 169.27M | 158.72M | 170.01M | 168.26M | 181.99M | 194.95M | EBIT |
| 10.84M | 4.33M | 4.26M | 1.86M | 11.42M | 9.68M | EBITDA |
| 13.35M | 7.93M | 4.26M | 9.75M | 23.07M | 19.88M | Net Income Common Stockholders |
| 7.34M | 2.94M | 2.54M | 3.12M | 12.89M | 11.55M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 1.89M | 16.89M | 21.61M | 20.19M | 23.17M | 22.14M | Total Assets |
| 6.30M | 60.30M | 66.12M | 70.71M | 78.73M | 58.88M | Total Debt |
| 1.57M | 13.61M | 13.09M | 15.76M | 18.18M | 1.18M | Net Debt |
| 46.34K | -3.27M | -8.52M | -4.43M | -4.99M | -20.95M | Total Liabilities |
| 18.91M | 34.31M | 31.47M | 39.19M | 41.92M | 25.62M | Stockholders Equity |
| -12.60M | 25.99M | 34.65M | 31.52M | 36.81M | 33.25M |
| Cash Flow | Free Cash Flow | ||||
| 12.88M | 9.95M | 3.76M | 6.43M | 12.53M | 15.64M | Operating Cash Flow |
| 14.29M | 12.20M | 6.83M | 7.96M | 16.27M | 18.33M | Investing Cash Flow |
| -1.41M | -2.25M | -3.06M | -1.53M | -3.73M | -2.68M | Financing Cash Flow |
| -8.43M | -14.42M | -2.36M | -8.95M | -11.45M | -12.42M |
LifeVantage Technical Analysis
Negative
13.82
Price Trends
17.03
Negative
17.36
Negative
13.46
Positive
Market Momentum
-0.87
Positive
35.22
Neutral
15.09
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFVN, the sentiment is Negative. The current price of 13.82 is below the 20-day moving average (MA) of 15.25, below the 50-day MA of 17.03, and above the 200-day MA of 13.46, indicating a neutral trend. The MACD of -0.87 indicates Positive momentum. The RSI at 35.22 is Neutral, neither overbought nor oversold. The STOCH value of 15.09 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LFVN.
LifeVantage Risk Analysis
LifeVantage disclosed 50 risk factors in its most recent earnings report. LifeVantage reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
LifeVantage Peers Comparison
Overall Rating
UnderperformOutperform
Sector (63)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $192.03M | 27.07 | 25.67% | 1.15% | 0.57% | 155.00% | |
70 Outperform | $217.37M | 28.96 | 4.98% | ― | 2.03% | -47.76% | |
66 Neutral | $742.79M | 2.72 | -31.74% | ― | -1.37% | 75.47% | |
66 Neutral | $476.78M | 11.54 | 7.76% | ― | -7.22% | -33.67% | |
63 Neutral | $20.41B | 13.98 | -16.01% | 3.26% | 1.30% | 5.01% | |
62 Neutral | $229.06M | 6.54 | 15.57% | 1.22% | -2.88% | -14.25% | |
55 Neutral | $143.29M | 69.45 | 1.02% | ― | -43.80% | -97.89% |
* Consumer Defensive Sector Average
Performance Comparison
LFVN
LifeVantage
13.82
7.72
126.56%
HLF
Herbalife
6.78
-1.32
-16.30%
JAKK
Jakks Pacific
18.66
-4.03
-17.76%
MED
Medifast
13.14
-18.37
-58.30%
NATR
Nature's Sunshine Products
11.70
-7.32
-38.49%
USNA
USANA Health
24.74
-19.23
-43.73%
LifeVantage Earnings Call Summary
Earnings Call Date: Feb 5, 2025 | % Change Since: -39.09% | Next Earnings Date: May 1, 2025
Earnings Call Sentiment Positive
The earnings call reflects a strong quarter for LifeVantage, driven by the successful launch and demand for the MindBody GLP-1 System, significant revenue growth, improved profitability metrics, and a solid cash position. However, challenges such as inventory constraints, a decline in certain international markets, and higher incentive expenses present notable challenges. The overall sentiment leans positive due to the outweighing highlights.Highlights
Significant Revenue Growth
Revenue for the second quarter was $67.8 million, representing sequential growth of nearly 44% from the first quarter and year-over-year growth of 31%.
Successful Product Launch
The MindBody GLP-1 System was launched in October and sold out within 13 days. Additional inventory was received mid-December, clearing backlog by the end of December.
Improved Profitability Metrics
Gross margins increased by 190 basis points year-over-year, and adjusted EBITDA more than doubled to $6.5 million or 9.6% of revenue.
Increase in Active Accounts
Active accounts in the Americas increased by 23,000 or 25% compared to Q1, with a 13% increase in independent consultants and a 31% increase in customers.
Positive Clinical Results
The MindBody GLP-1 System led to a 140% increase in natural GLP-1 production, reducing visceral fat by up to 27% and total body fat by up to 5.5%.
Strong Cash Position
$21.6 million in cash and no debt at the end of the second quarter.
Lowlights
Inventory Challenges
MindBody GLP-1 System faced supply chain issues with inventory selling out quickly and causing backorders.
Decline in Asia-Pacific and Europe Revenue
Revenue in the Asia-Pacific and Europe region decreased 15.5%, primarily due to a 13.9% decrease in active accounts and negative currency impacts.
Higher Incentive Expenses
Commissions and incentive expenses increased to 48% of revenue from 42.1% in the prior year due to higher incentive-related expenses.
Company Guidance
During the second quarter of fiscal 2025, LifeVantage Corporation reported impressive financial metrics, driven by the success of their newly launched MindBody GLP-1 System. The company achieved a revenue of $67.8 million, marking a sequential growth of nearly 44% from the first quarter and a year-over-year increase of 31%. Gross margins improved by 190 basis points compared to the previous year, while adjusted EBITDA more than doubled to $6.5 million, representing 9.6% of revenue. The launch led to a significant increase in active accounts, particularly in the Americas, where they grew by 25% compared to Q1. Additionally, subscription metrics exceeded 70%, spurred by the MindBody System's long-term lifestyle benefits. The product demonstrated significant clinical results, including an average 140% increase in natural GLP-1 production, contributing to a reduction in visceral fat by up to 27% and total body fat by 5.5%. The company's strategic focus remains on sustaining growth, enhancing digital capabilities, and preparing for the international rollout of MindBody, with fiscal 2025 revenue guidance set between $235 million and $245 million.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.